Current issues regarding the use of pneumococcal conjugate and polysaccharide vaccines in Australian children

Journal of Paediatrics and Child Health

Volumn 41, Issue 4, 2005, Pages 201-208

  Mackenzie, Grant A ^a,b,c   Carapetis, Jonathan R ^d,e   Morris, Peter S ^a,b,c   Leach, Amanda Jane ^a,b  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b CHARLES DARWIN UNIVERSITY   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bacterial vaccines; Biological products; Immunologic and biological factors; Pneumococcal vaccines; Vaccines

Indexed keywords

ANTIBIOTIC AGENT; PNEUMOCOCCUS VACCINE;

ANAPHYLAXIS; AUSTRALIA; BACTEREMIA; CHILD; CHILDHOOD MORTALITY; CLINICAL FEATURE; DEATH; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; EDEMA; EPIDEMIOLOGICAL DATA; ERYTHEMA; FAMILY; FEBRILE CONVULSION; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; INJECTION PAIN; IRRITABILITY; LONG TERM CARE; MENINGITIS; MUSCLE HYPOTONIA; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEPTICEMIA; SEROTYPE; SIDE EFFECT; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; VACCINATION; VOMITING;

AUSTRALIA; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS;

EID: 18444400232     PISSN: 10344810     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2005.00588.x     Document Type: Review

References (64)

1. National Health and Medical Research Council. The Australian Immunisation Handbook. 8th edn. Commonwealth of Australia, Canberra, Australia, 2003.
2. Roche P, Krause V, Andrews R et al. Invasive pneumococcal disease in Australia, 2002. Commun. Dis. Intell. 2003; 27: 466-77.
3. McIntyre PB, Gilmour RE, Gilbert GL, Kakakios AM, Mellis CM. Epidemiology of invasive pneumococcal disease in urban New South Wales. 1997-99. Med J. Aust. 2000; 173: S22-6.
4. National Perinatal Statistics Unit. Australia's mothers and babies 2000. Randwick (Sydney) 2003, series 12. The Australian Institute of Health and Welfare, Canberra, Australia.
5. National Hospital Morbidity Database 2001-02. Australian Institute of Health and Welfare, Canberra, Australia, 2003. Available from URL: http://www.aihw.gov.au/hospitaldata/datacubes/index.html.
6. Fireman B, Black SB, Shinefield HR et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr. Infect. Dis. J. 2003; 22: 10-16.
7. Black SB, Shinefield HR, Ling S et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 2002; 21: 810-15.
8. Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schwartz B. Risk factors for invasive pneumococcal disease in children: A population-based case-control study in North America. Pediatrics 1999; 103: E28.
9. McIntyre P, Gilmour R, Watson M. Differences in the epidemiology of invasive pneumococcal disease, metropolitan NSW, 1997-2001. NSW Public Health Bull. 2003; 14: 85-9.
10. Gessner BD, Ussery XT, Parkinson AJ, Breiman RF. Risk factors for invasive disease caused by Streptococcus pneumoniae among Alaska native children younger than two years of age. Pediatr. Infect. Dis. J. 1995; 14: 123-8.
11. Takala AK, Jero J, Kela E, Ronnberg P, Koskenniemi E, Eskola J. Risk factors for primary invasive pneumococcal disease among children in Finland. JAMA 1995; 11: 859-4.
12. Davidson M, Schraer CD, Parkinson AJ et al. Invasive pneumococcal disease in an Alaska native population, 1980 through 1986. JAMA 1989; 261: 715-8.
13. Shinefield H, Black S, Ray P, Fireman B, Schwalbe J, Lewis E. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr. Infect. Dis. J. 2002; 21: 182-6.
14. Reefhuis J, Honein MA, Whitney CG et al. Risk of bacterial meningitis in children with cochlear implants. N. Engl. J. Med. 2003; 349: 435-45.
15. Nuorti JP, Butler JC, Farley MM et al. Cigarette smoking and invasive pneumococcal disease. Active bacterial core surveillance team. N. Engl. J. Med. 2000; 342: 681-9.
16. Robinson KA, Baughman W, Rothrock G et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285: 1729-35.
17. O'Brien KL, Moulton LH, Reid R et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: Group randomised trial. Lancet 2003; 362: 355-61.
18. Roche P, Krause V. Invasive pneumococcal disease in Australia, 2001. Commun. Dis. Intell. 2002; 26: 505-19.
19. Krause VL, Reid SJC, Merianos A. Invasive pneumococcal disease in the Northern Territory of Australia, 1994-98. Med. J. Aust. 2000; 173: S27-31.
20. Obaro SK, Huo Z, Banya WAS et al. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children. Pediatr. Infect. Dis. J. 1997; 16: 1135-40.
21. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 2000; 19: 187-95.
22. National Immunisation Program. Australian Government, Department of Health and Ageing. Universal Childhood Pneumococcal Vaccination Program, 2004. Available from URL: http://www.immunise.health.gov.au/universal/providers.htm.
23. Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J. Infect. Dis. 1983; 148: 131-7.
24. Pomat WS, Lehmann D, Sanders RC et al. Immunoglobulin G antibody responses to polyvalent pneumococcal vaccine in children in the highlands of Papua New Guinea. Infect. Immun. 1994; 62: 1848-53.
25. Borgono JM, McLean AA, Vella PP et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc. Soc. Exp. Biol. Med. 1978; 157: 148-54.
26. Australian Government. Department of Health and Ageing. Schedule of Pharmaceutical Benefits. Commonwealth of Australia, Canberra, Australia, 2004.
27. National Health and Medical Research Council. The Australian Immunisation Handbook. 7th edn. Commonwealth of Australia, Canberra, Australia, 2000.
28. Jackson LA, Benson P, Sneller VP et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999; 281: 243-8.
29. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 2003; 349: 1341-8.
30. Kilpi T, Ahman H, Jokinen J et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: Randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis. 2003; 37: 1155-64.
31. Madhi SA, Klugman KP, The Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat. Med. (Serial Online) 2004 11 July. Available from URL: http://www.nature.com/naturemedicine/; doi:10.1038/nm1077
32. Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 2001; 344: 403-9.
33. Karma P, Palmu A, Verho J, Makela PH, Kilpi T. Effect of the seven valent PNCCRM vaccine on otitis-related surgery. Proceedings of the 8th International Symposium on Recent Advances in Otitis Media; 3-7 June 2003, Fort Lauderdale, USA, 2003; 137.
34. Dagan R, Sikuler-Cohen M, Zamir O, Janco J, Givon-Levi N, Fraser D. Effect of a conjugate pneumococal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. PIDJ 2001; 20: 951-8.
35. Veenhoven R, Bogaert D, Uiterwaal C et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: A randomised study. Lancet 2003; 361: 2189-95.
36. Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 2003; 348: 1737-46.
37. Schuchat A, Flannery B, Heffernan R et al. Invasive pneumococcal disease in HIV-AIDS: Has introduction of 7-valent pneumococcal conjugate vaccine (PCV-7) reduced HIV-related disease burden in the US? Proceedings of the 4th International Symposium on Pneumococci and Pneumococcal Diseases; 9-13 May 2004, Helsinki, Finland. Abstract EPI-05, p. 36.
38. Karma P, Pukander J, Sipila M et al. Prevention of otitis media in children by pneumococcal vaccination. Am. J. Otolaryngol. 1985; 6: 173-84.
39. Rosen C, Chrtstensen P, Henrichsen J, Hovelius B, Prellner K. Beneficial effect of pneumococcal vaccination on otitis media in children over two years old. Int. J. Pediatr. Otorhinolaryngol. 1984; 7: 239-46.
40. Riley ID, Lehmann D, Alpers MP, Marshall TF, Gratten H, Smith D. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. Lancet 1986; 2: 877-81.
41. Riley ID, Everingham FA, Smith DE, Douglas RM. Immunisation with a polyvalent pneumococcal vaccine. Effect of respiratory mortality in children living in the New Guinea highlands. Arch. Dis. Child. 1981; 56: 354-7.
42. Lehmann D, Marshall TF, Riley ID, Alpers MP. Effect of pneumococcal vaccine on morbidity from acute lower respiratory tract infections in Papua New Guinean children. Ann. Trop. Paediatr. 1991; 11: 247-257.
43. Douglas RM, Miles HB. Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children. J. Infect. Dis. 1984; 149: 861-9.
44. Straetemans M, Sanders EA, Veenhoven RH, Schilder AGM, Damoiseaux RAMJ, Zielhuis GA. Pneumococcal vaccines for preventing otitis media. Cochrane Database Syst. Rev. 2002; CD001480. Available from URL: http://www.cochrane.org.
45. Teele DW, Klein JO, Bratton L et al. Use of pneumococcal vaccine for prevention of recurrent acute otitis media in infants in Boston. The Greater Boston Collaborative Otitis Media Study Group. Rev. Infect. Dis. 1981; 3(Suppl): S113-18.
46. Sloyer JL Jr, Ploussard JH, Howie VM. Efficacy of pneumococcal polysaccharide vaccine in preventing acute otitis media in infants in Huntsville, Alabama. Rev. Infect. Dis. 1981; 3(Suppl): S119-23.
47. Makela PH, Leinonen M, Pukander J, Karma P. A study of the pneumococcal vaccine in prevention of clinically acute atttacks of recurrent otitis media. Rev. Infect. Dis. 1981; 3(Suppl): S124-32.
48. Douglas RM, Hansman D, McDonald B, Paton J, Kirke K. Pneumococcal vaccine in aboriginal children-a randomized controlled trial involving 60 children. Community Health Stud. 1986; 10: 189-96.
49. Schuller DE. Prophylaxis of otitis media in asthmatic children. Pediatr. Infect. Dis. 1983; 2: 280-3.
50. Leask J. Vaccination and risk communication: Summary of a workshop, Arlington Virginia, USA, 5-6 October 2000. J. Paediatr. Child Health. 2002; 38: 124-8.
51. Product Information, Prevenar® 0.5 mL. Wyeth Pty Ltd. Australia. 3 April 2003.
52. Product Information, Pneumovax 23®. Merck Sharp and Dohme Pty Ltd, Australia. 16 July 2001.
53. Lawrence G, Menzies R, Burgess M et al. Surveillance of adverse events following immunisation: Australia, 2000-02. Commun. Dis. Intell. 2003; 27: 307-23.
54. Kuppermann M, Nease RF Jr, Ackerson LM, Black SB, Shinefield HR, Lieu TA. Parents' preferences for outcomes associated with childhood vaccinations. Pediatr. Infect. Dis. J. 2000; 19: 129-33.
55. Ritov II, Baron J. Protected Values and Omission Bias. Organ Behav. Hum. Decis. Process. 1999; 79: 79-94.
56. The Australian Meningococcal Surveillance Program. Annual report of the Australian Meningococcal Surveillance Programme. 2000. Commun. Dis. Intell. 2001; 25: 113-21.
57. The Australian Meningococcal Surveillance Program. Annual report of the Australian Meningococcal Surveillance Programme, 2001. Commun. Dis. Intell. 2002; 26: 407-18.
58. The Australian Meningococcal Surveillance Program. Annual report of the Australian Meningococcal Surveillance Programme, 2002. Commun. Dis. Intell. 2003; 27: 196-208.
59. Surveillance Annual Reports: Infectious Diseases, Epidemiology and Surveillance. Department of Human Services, State Government of Victoria, Australia. Victorian government health information web site. 2002. Available from URL: http://www.health.vic.gov.au/ideas/downloads/annual_rpts/ SNID2002_InvasiveMeningococcalDisease.pdf.
60. Shigematsu M, Davison KL, Charlett A, Crowcroft NS. National enhanced surveillance of meningococcal disease in England, Wales and Northern Ireland, January 1999-June 2001. Epidemiol. Infect. 2002; 129: 459-70.
61. Senator Kay Patterson, Minister for Health and Ageing. Boost to Australia's national immunisation program. 19 September 2003. Available from URL: http://www.health.gov.au/mediarel/yr2003/kp/kp03205.htm.
62. Leask J. A free vaccine with too high a cost. The Sydney Morning Herald 2003; 24 September (Sect. News and Features; p. 13).
63. McIntyre PB, Nolan TM. Conjugate pneumococcal vaccines for non-Indigenous children in Australia. Med. J. Aust. 2000; 173: S54-7.
64. Burgess MA, McIntyre PB. Vaccines: The new Australian best-practice schedule. Med. J. Aust. 2004; 180: 494-6.